183 filings
Page 9 of 10
8-K
sg2z6vmeis8
10 Mar 16
KemPharm, Inc. Reports Q4 and Year End 2015 Results
12:00am
8-K
6z6nb0sxeunvej4zws
17 Feb 16
Departure of Directors or Certain Officers
12:00am
8-K
fhq5dzbxmd93hh
10 Feb 16
FDA Grants Priority Review to KemPharm for KP201/APAP NDA
12:00am
8-K
hkmdmkl sj8y76ue
9 Feb 16
KemPharm Announces Pricing of $75.0 Million 5.50% Senior Convertible Notes Due 2021
12:00am
8-K
897p0mgc7fnm4if98pg
11 Jan 16
Entry into a Material Definitive Agreement
12:00am
8-K
vgr wbac8h0
30 Dec 15
KemPharm, Inc. Expands Pain Therapy Pipeline with Discovery of KP746
12:00am
8-K
dz32joo7yogc01aadb7
18 Dec 15
Entry into a Material Definitive Agreement
12:00am
8-K
lpmhgw g4ny
15 Dec 15
Regulation FD Disclosure
12:00am
8-K
7ar0ww
8 Dec 15
Other Events
12:00am
8-K
cawrl77l
12 Nov 15
KemPharm, Inc. Reports Q3 2015 Results
12:00am
8-K
k0i173jc79hcxcas4bdo
21 Oct 15
KemPharm, Inc. Completes Human Abuse Liability Program for KP201/APAP
12:00am
8-K
bd2cym08 wra8ahtd0z
15 Oct 15
Unregistered Sales of Equity Securities
12:00am
8-K
sd0ey2as6c9n3ga
30 Sep 15
KemPharm Reports Positive Data Demonstrating Tamper-Resistant Properties of KP201/APAP
12:00am
8-K
gp4y46 2fx1sb4
24 Sep 15
Provides Updates on Clinical Development Pipeline and Anticipated NDA Filings
12:00am
8-K
aak0 vgvz
23 Sep 15
Other Events
12:00am
8-K
9ej8dqnuk58txwr
9 Sep 15
Departure of Directors or Certain Officers
12:00am
8-K
php9wp2bpk
13 Aug 15
KemPharm, Inc. Announces Positive Data from Intranasal Human Abuse Liability Study of KP201/APAP; Reports Q2 2015 Results
12:00am
8-K
vc0e1lxvgtif
12 Aug 15
35th Annual Growth Conference
12:00am
8-K
zcz9 tj8ipt1p
26 Jun 15
KemPharm, Inc. Announces Changes to Senior Leadership to Target Strategic Opportunities
12:00am
8-K
jr4dseqexii8f5
16 Jun 15
Other Events
12:00am